Ing. Dana Dvořáková, CSc.
Pracoviště: LF MU a FN Brno, IHOK a CEITEC (Černopolní 9, 625 00 Brno)
E-mail: ddvorak@fnbrno.cz
Odborné práce publikované na Linkos.cz
Níže se zobrazuje autorství některých typů informací, které jsou součástí databazí na Linkos a také autorství článků pro pacienty na Linkos. Vypisují se knihy, články v Klinické onkologii a onkologické péči, tuzemská abstrakta zažazená do databáze abstrakt, brožury pro pacienty a také texty pro pacienty na Linkos. Rejstřík v žádném případě není úplným autorským rejstříkem, protože nejpodstatnější publikace a sice publikace v zahraničních časopisech tento způsob nezobrazuje.
Publikované knihy
Publikovaná abstrakta
- A NOVEL MGB PROBE-BASED ASSESSMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CARRYING NPM1 (NUCLEOPHOSMIN) EXON 12 MUTATIONS
- ACUTE MYELOID LEUKEMIAS WITH RECURRENT GENETIC ABNORMALITIES: FREQUENT ASSESSMENT OF MINIMAL RESIDUAL DISEASE AND TREATMENT OF MOLECULAR RELAPSE
- Acute toxicities followed by management of locally advanced non-small cell lung cancer – TGF-β1 as a predictor of radiation pneumonitis.
- Acute toxicities followed by management of locally advanced nonsmall cell lung cancer – TGF-B1 as a predictor
- ACHIEVEMENT OF BCL-2/IGH NEGATIVITY IN PERIPHERAL BLOOD/BONE MARROW IS ASSOCIATED WITH BETTER CLINICAL OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA
- Amifostine as a radioprotector in the management of advanced non-small cell lung cancer – histopathological features
- AN ATYPICAL JUNCTION OF BCR-ABL GENE AS MOLECULAR MARKER FOR QUANTITATIVE MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
- Analýza genové exprese u folikulárního lymfomu pomocí oligonukleotidových microarrays
- AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: STILL NOT OUT OF FASHION
- BONE MARROW VERSUS PERIPHERAL BLOOD: COMPARISON OF THE CHIMERISM ANALYSIS
- BONE MARROW/PERIPHERAL BLOOD POSITIVITY OF BCL-2/IGH REARRANGEMENT IN PATIENTS WITH FOLLICULAR LYMPHOMA BEFORE TREATMENT HAS NO PROGNOSTIC SIGNIFICANCE
- CEBPA GENE MUTATIONAL STATUS: A COMPLETE SCREENING USING HIGH-RESOLUTION MELT CURVE ANALYSIS
- CLOFARABINE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA – SINGLE CENTER EXPERIENCE
- COMPLETE HEMATOLOGIC REMISSION BUT NOT MOLECULAR REMISSION IS ASSOCIATED WITH PROLONGED SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Constitutive Activation of STAT1 and STAT3 Proteins on Serine and Tyrosine Residues Were Found in Majority of CLL
- CONSTITUTIVE ACTIVATION OF STAT1 AND STAT3 PROTEINS WITHOUT INTERFERON INDUCIBILITY: RELEVANCE TO THERAPY IN IGVH-UNMUTATED CLL PATIENTS
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DEFINITION AND VALIDATION OF NOVEL PROGNOSTIC MARKERS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
- Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1, CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression.
- DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML)
- Detection of Molecular Relapse of AML by Very Frequent Quantitative Monitoring of Different Molecular Markers (Fusion Transcripts and WT1) in Different Compartments (Peripheral Blood-PB, Bone Marrow-BM, and Selected CD34+ Bone Marrow Cells) and Its T
- DETECTION OF MOLECULAR RELAPSE OF AML BY VERY FREQUENT QUANTITATIVE MONITORING OF DIFFERENT MOLECULAR MARKERS IN DIFFERENT COMPARTMENTS AND ITS TREATMENT WITH CHEMOTHERAPY OR GEMTUZUMAB OZOGAMICIN
- Detekce herpetických virů u imunokompromitovaných pacientů metodou „real-time“ PCR
- DYNAMICS OF LINEAGE-SPECIFIC CHIMERISM IN PATIENTS AFTER NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION
- EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
- CHARACTERIZATION OF P53 AND ATM ABNORMALITIES IN B-CLL PATIENTS
- Chimerism Status as a Possible Marker of Incipient Disease Relapse in Patients with AML.
- IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
- IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
- IS NONMYELOABLATIVE TRANSPLANT SUFFICIENT TO CURE CHRONIC MYELOID LEUKEMIA?
- Izolace RNA pro účely RT-PCR, Real-Time PCR a DNA čipů z tkání fixovaných ve formalínu a archivovaných v parafinových bločcích
- LONG-TERM RESULTS OF REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 1ST CHRONIC PHASE CML
- MICROCHIMERISM – LOOK INTO THE INCIPIENT AML RELAPSE?
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- MOLECULAR ANALYSIS OF IGVH GENE MUTATIONAL STATUS AS A PROGNOSTIC FACTOR IN B – CLL WITHIN CZECH PATIENTS
- Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients
- MONITORING OF MRD BY NPM1 MUTATIONS FROM MRNA AND GENOMIC DNA AND ITS COMPARISON WITH EXPRESSION OF WT1 GENE IN AML PATIENTS
- MONITORING OF THE STATUS OF BOTH P53 ALLELES IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RELEVANCE TO PROGNOSIS AND TREATMENT
- Mutační analýza genu EGFR u pacientů s nemalobuněčným karcinomem plic (NSCLC) ve FN Brno.
- PERSISTENCE OF LYMPH NODE T(14;18) BEARING CELLS IN FOLLICULAR LYMPHOMA PATIENTS IN CLINICAL COMPLETE REMISSION: PROOF OF PRINCIPLE FOR MAINTENANCE THERAPY?
- PERSISTENT MICROCHIMERISM IN BONE MARROW: INFLUENCE OF MESENCHYMAL STEM CELLS
- Porovnání dozimetrické a biologické predikce akutní toxicity při léčbě
- PREDICTION OF IMATINIB THERAPY RESPONSE: A ROLE OF INTRACELLULAR TRANSPORTERS HOCT-1 AND ABCB1
- Profilování genové exprese u lymfoidních malignit: Validace vybraných molekulární markerů u difúzního velkobuněčného B-lymfocytárního lymfomu (DLBCL)
- Prognostický význam mutačního stavu genu TP53 u pacientů s B-buněčnou chronickou lymfocytární leukémií – význam monitorováni obou alel.
- QUANTITATIVE DETECTION OF MINIMAL RESIDUAL DISEASE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED TAQ-MAN PROBES AND IGH-RQ PCR
- Sledování defektů ve fosforylaci STAT1, STAT3 proteinů a jejich význam pro stanovení prognózy u CLL pacientů
- Sledování exprese vybraných genů u pacientů s B-buněčnou chronickou lymfocytární leukémií – záchyt změny leukemického klonu vlivem terapie
- Studie OPERA -Non-interventional Observation of Prescription Habits of Prophylactic Pegfilgrastim in Patients treated with Higher Risk CT Regimens in the Czech Republic.
- T(14;18) IN FOLLICULAR LYMPHOMA: A REAL- TIME (PCR) FOR A REAL LIFE….?
- The cytoprotective effect of amifostine in concomitant chemoradiotherapy of locally advanced non-small cell lung cancer
- The Plateau of BCR-ABL Transcript Level =;>0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
- TREATMENT OF MOLECULAR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
- UNEXPECTED ANTAGONISTIC EFFECT OF RITUXIMAB WITH PROCARBAZINE DISCLOSED DURING AN IN VITRO TESTING OF RITUXIMAB-MEDIATED SENSITIZATION OF B-CELL LINES TO COMMONLY USED ANTICANCER DRUGS
- Úskalí molekulární diagnostiky Ewingova sarkomu / PNET
- Využití long-oligonucleotide arrayCGH v diagnostice leukémií.
- Využití RNA interference při regulaci genové exprese antionkogenu p53
- Využití RNA interference při regulaci genové exprese antionkogenu p53
- Využití TGF-β1 k predikci akutní plicní toxicity při chemoradioterapii NSCLC.